Adoption of the concept of Risk-Based Budgeting could help maintain the trial budget or even save the whole clinical trial.
Get ready for ACT's upcoming Peer Exchange about the electronic elements of a clinical trial.
Use cases show benefits of unlocking data to improve signal and adverse event detection.
Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help attain a more complete picture of how an individual’s complex biology impacts their health profile.
Statistical methods used via this technique in centralized monitoring.
Implementing new strategies with the use of patient-reported outcomes.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
Evolving technologies include modification of receptors on T cells to better target tumor microenvironments and minimize off-tumor cross-reactivity.
The conundrum of missing data vs. inter-rater variability.
Advancing risk-based auditing one step further by identifying the underlying process deficiencies to enable improved corrective and preventive actions.
Study evaluates the use of AI-supported medical coding module.
While many groups rely on manual chemistry processes, innovative platforms have emerged that allow these protocols to be executed on custom automation systems.
Brian Ongioni, chief product officer, uMotif, discusses how AI and machine learning can enhance patient-reported outcomes by capturing meaningful feedback at scale and ensuring patient voices are reflected throughout the clinical trial lifecycle.
Evolving technologies include modification of receptors on T cells to better target tumor microenvironments and minimize off-tumor cross-reactivity.
Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.
Tuesday, June 22, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Minimizing protocol deviations is a simple, yet effective way for sites to keep trials patient-centric.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
While the world focuses on COVID-19, this article provides insight on the current state of the market for antimicrobial resistant (AMR) medicines.
An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.
While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.
A discussion of how the coronavirus pandemic will have a multitude of impacts on the conduct of trials, as well as on the industry itself.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
All stakeholders must play part in increasing implementation.
The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.
From design and trial start-up to conduct and analysis, there is enormous potential for applications of artificial intelligence within clinical trials to have a profound impact on human health.
Exploring the implications of FDA’s renewed focus and commitment to expand the use of accelerated approval for gene therapy products.